This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Campos, S. Search for Related Content PubMed PubMed Citation Articles by Campos, S.

Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer

Dana-Farber Cancer Institute, Brigham and Women’s Cancer Center, Boston, Massachusetts, USA

Correspondence: Susana Campos, M.D., M.P.H., Dana-Farber Cancer Institute, Brigham and Women’s Cancer Center, 44 Binney Street, Boston, Massachusetts 02115, USA. Telephone: 617-632-3800; Fax: 617-632-3479; e-mail: Susana_Campos{at}dfci.harvard.edu

Conventional anthracyclines, particularly doxorubicin, have played an important role in the treatment of patients with breast cancer for many decades. Conventional doxorubicin has shown excellent antitumor activity in the metastatic, neoadjuvant, and adjuvant settings. However, its clinical utility is limited due to acute and chronic toxicities, particularly cardiotoxicity, myelosuppression, nausea and vomiting, and alopecia. Liposomal doxorubicin formulations (liposomal doxorubicin [D-99] and pegylated liposomal doxorubicin) currently under investigation for the treatment of breast cancer have demonstrated similar efficacies and favorable toxicity profiles compared with conventional doxorubicin in patients with metastatic breast cancer. These agents have also shown efficacy and tolerability in several small studies as neoadjuvant therapy in patients with locally advanced breast cancer. While there are currently no studies with liposomal doxorubicin or pegylated liposomal doxorubicin as adjuvant therapy, their demonstrated activities and tolerabilities in the metastatic and neoadjuvant settings provide the rationale for the future study of these agents in adjuvant therapy for patients with early-stage breast cancer.

Key Words. Anthracyclines • Liposome • Adjuvant chemotherapy • Neoadjuvant therapy • Breast neoplasms

This article has been cited by other articles:

				J. J.M. Teunissen, D. J. Kwekkeboom, and E. P. Krenning Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [177Lu-DOTA0,Tyr3]octreotate J. Clin. Oncol., July 1, 2004; 22(13): 2724 - 2729. [Abstract] [Full Text] [PDF]

				J. O'Shaughnessy Liposomal Anthracyclines for Breast Cancer: Overview Oncologist, August 1, 2003; 8(90002): 1 - 2. [Full Text] [PDF]

				E. Rivera Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update Oncologist, August 1, 2003; 8(90002): 3 - 9. [Abstract] [Full Text] [PDF]

				A. C. Wolff Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer Oncologist, August 1, 2003; 8(90002): 25 - 30. [Abstract] [Full Text] [PDF]